VYNE vs. BOLT, EYEN, CARA, UNCY, NXTC, LEXX, DRRX, JAN, CASI, and SNSE
Should you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Bolt Biotherapeutics (BOLT), Eyenovia (EYEN), Cara Therapeutics (CARA), Unicycive Therapeutics (UNCY), NextCure (NXTC), Lexaria Bioscience (LEXX), DURECT (DRRX), JanOne (JAN), CASI Pharmaceuticals (CASI), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical preparations" industry.
Bolt Biotherapeutics (NASDAQ:BOLT) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.
86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 28.4% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 1.8% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Bolt Biotherapeutics had 3 more articles in the media than VYNE Therapeutics. MarketBeat recorded 10 mentions for Bolt Biotherapeutics and 7 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.26 beat Bolt Biotherapeutics' score of 0.79 indicating that Bolt Biotherapeutics is being referred to more favorably in the media.
VYNE Therapeutics has lower revenue, but higher earnings than Bolt Biotherapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Bolt Biotherapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.
Bolt Biotherapeutics has a net margin of -878.58% compared to Bolt Biotherapeutics' net margin of -6,874.47%. VYNE Therapeutics' return on equity of -51.18% beat Bolt Biotherapeutics' return on equity.
Bolt Biotherapeutics received 56 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Bolt Biotherapeutics an outperform vote while only 58.54% of users gave VYNE Therapeutics an outperform vote.
Bolt Biotherapeutics currently has a consensus price target of $4.75, indicating a potential upside of 452.20%. VYNE Therapeutics has a consensus price target of $5.75, indicating a potential upside of 99.65%. Given VYNE Therapeutics' higher possible upside, equities analysts plainly believe Bolt Biotherapeutics is more favorable than VYNE Therapeutics.
Summary
Bolt Biotherapeutics beats VYNE Therapeutics on 13 of the 17 factors compared between the two stocks.
Get VYNE Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VYNE Therapeutics Competitors List
Related Companies and Tools
